A comparison of bronchodilating effects of salmeterol and oxitropium bromide in stable chronic obstructive pulmonary disease

Respiratory Medicine

Volumn 92, Issue 2, 1998, Pages 354-357

  Cazzola, M ^a,c   Matera, M G ^b   Di Perna, F ^a   Calderaro, F ^c   Califano, C ^a   Vinciguerra, A ^a  

^a CARDARELLI HOSPITAL   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; OXITROPIUM BROMIDE; SALMETEROL;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; ELECTROCARDIOGRAPHY; FORCED EXPIRATORY VOLUME; HUMAN; INHALATIONAL DRUG ADMINISTRATION; LUNG FUNCTION; MALE; METERED DOSE INHALER; PRIORITY JOURNAL; PULSE RATE; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TIME;

EID: 0031930436     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0954-6111(98)90121-4     Document Type: Article

References (17)

1. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152: S72-S120.
2. Chapman KR. Therapeutic approaches to chronic obstructive pulmonary disease: an emerging consensus. Am J Med 1996; 100 (Suppl. 1A): 5S-10S.
3. Matera MG, Cazzola M, Vinciguerra A et al. A comparison of the bronchodilating effects of salmeterol, salbutamol and ipratropium bromide in patients with chronic obstructive pulmonary disease. Pulm Pharmacol 1995; 8: 267-271.
4. Minette A, Marcq M. Oxitropium bromide (Ba 253), an advance in the field of anticholinergic bronchodilating treatments. Rev Inst Hyg Mines 1979; 34: 115-123.
5. American Thoracic Society. Standards for diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1987; 136: 225-244.
6. Berger R, Smith D. Acute postbronchodilator changes in pulmonary function parameters in patients with chronic airways obstruction. Chest 1988; 93: 541-546.
7. Koch GG. The use of nonparametric methods in the statistical analysis of the two period change-over design. Biometrics 1972; 28: 577-584.
8. Tashkin DP, Ashutosh K, Blecker ER et al. Comparison of the anticholinergic bronchodilator ipratropium bromide with metaproterenol in chronic obstructive pulmonary disease. Am J Med 1986; 81 (Suppl. 5A): 59-67.
9. Braun SR, McKenzie WN, Copeland C, Knight L, Ellersieck M. A comparison of the effect of ipratropium and albuterol in the treatment of chronic obstructive airway disease. Arch Intern Med 1989; 149: 544-547.
10. Skorodin MS, Gross NJ, Moritz T et al. Oxitropium bromide, a new anticholinergic bronchodilator. Ann Allergy 1986; 56: 229-232.
11. Frith PA, Jenner B, Dangerfield RN, Atkinson J, Drennan C. Oxitropium bromide. Dose-response and time response study of a new anticholinergic bronchodilator drug. Chest 1986; 89: 249-253.
12. Ikeda A, Nishimura K, Koyama H, Izumi T. Comparative dose-response study of three anticholinergic agents and fenoterol using a metered dose inhaler in patients with chronic obstructive pulmonary disease. Thorax 1995; 50: 62-66.
13. Cazzola M, Matera MG, Santangelo G et al. Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study. Repir Med 1995; 89: 357-362.
14. Faurschou P. Chronic dose-raging studies with salmeterol. Eur Respir Rev 1991; 1: 282-287.
15. Lal S, Eyre-Brook A, Mitra SK, Gribben D. Oxitropium bromide in chronic bronchitis. Res Clin Forums 1991; 13 (No. 2, part 2): 29-36.
16. Tashkin DP. Multiple dose regimens. Impact on compliance. Chest 1995; 107: 176S-182S.
17. Matera MG, Caputi M, Cazzola M. A combination with clinical recommended dosages of salmeterol and ipratropium is not more effective than salmeterol alone in patients with chronic obstructive pulmonary disease. Respir Med 1996; 90: 497-499.